Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 20/20 | 0.64 |
| ▸ | CA2 | P00918 | 20/20 | 0.64 |
| ▸ | CA9 | Q16790 | 20/20 | 0.64 |
| ▸ | CA12 | O43570 | 16/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447267 | 0.86 | CA1 (0.51) | CA1CA2CA9CA12CA14 | |
| SCHEMBL5392577 | 0.84 | CA1 (0.48) | CA1CA2CA9CA12 | |
| SCHEMBL5453190 | 0.84 | CA12 (0.48) | CA1CA2CA9CA12 | |
| SCHEMBL5392856 | 0.83 | KMT2A (0.55) | CA1CA2CA9CA12 | |
| SCHEMBL5383344 | 0.82 | CA1 (0.58) | CA1CA2CA9CA12CA14 | |
| SCHEMBL5420671 | 0.82 | LMNA (0.44) | CA1CA2CA9CA12 | |
| SCHEMBL5392801 | 0.81 | LMNA (0.43) | CA1CA2CA9CA12 | |
| SCHEMBL14428525 | 0.81 | LMNA (0.58) | — | |
| SCHEMBL5380690 | 0.81 | EGFR (0.46) | CA1CA2CA9CA12 | |
| SCHEMBL5376199 | 0.81 | LMNA (0.57) | CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-7223759-B2 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | ANADYS PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | CA1 4865/4885CA2 4432/4885CA9 3999/4885 |
| US-20050239827-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compouds | AMPD3, AAAS, PEPD | CA1 4538/4885CA2 3795/4885CA9 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.